Last reviewed · How we verify
gender affirming hormone therapy
At a glance
| Generic name | gender affirming hormone therapy |
|---|---|
| Sponsor | Celia Bañuls |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Body Composition Assessment in Transgender Population.
- The Effect of Gender-affirmative Measures on Breast Perception in Trans Men
- Effects of Resistance Exercise Among TGD Individuals Initiating Estrogen-Based Gender-Affirming Hormone Therapy (NA)
- Effects of Gender-Affirming Hormone Therapy on Cardiovascular, Metabolic, and Mental Health Outcomes in Transgender Adults.
- Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study
- Gynaecological Care for Transgender People in France in 2024.
- Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study
- Cardiomodulatory Effects of Gender-Affirming Hormone Therapy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- gender affirming hormone therapy CI brief — competitive landscape report
- gender affirming hormone therapy updates RSS · CI watch RSS
- Celia Bañuls portfolio CI